Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Reinforces Positive Outcomes of Endari® Clinical Trials, Including Efficacy Findings That Led to FDA ApprovalSeptember 24, 2019

Summary review of the clinical trials and efficacy findings for Endari.

Emmaus Life Sciences Announces Withdrawal of Marketing Authorization Application to European Medicines AgencySeptember 19, 2019

Emmaus Life Sciences to withdraw MAA

Emmaus Life Sciences Huddles Up with SCDAAMI to Host “Sideline Sickle Cell” Community Town Hall in DetroitSeptember 18, 2019

Campaign spokesperson Solomon Wilcots will be joined by fellow NFL veteran player Jocelyn Borgella of the Detroit Lions, Dr. Ahmar Zaidi and Dr. Michael Callaghan of the Children’s Hospital of Michigan and the Sickle Cell Disease Association of America Michigan Chapter (SCDAAMI)

Emmaus Life Sciences to be Delisted from Nasdaq Stock Market Following HearingSeptember 10, 2019

Company Committed to Listing on Major Exchange

Emmaus Life Sciences Granted European Patent for use of Pharmaceutical-grade L-glutamine in Treating DiverticulosisSeptember 03, 2019

Related patents granted in the United States, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia; Patents pending in Brazil and other countries